Lapatinib-d4 (tosylate)

Lapatinib-d4 (tosylate)

• CAS Number: 2749856-05-9
• UNSPSC Description: Lapatinib-d4 (GW572016-d4) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1][2].
• Target Antigen: Autophagy; EGFR; Ferroptosis; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;Autophagy;JAK/STAT Signaling;Others;Protein Tyrosine Kinase/RTK
• Field of Research: Cancer
• Smiles: O=S(O)(C1=CC=C(C=C1)C)=O.CS(C([2H])([2H])C([2H])([2H])NCC2=CC=C(O2)C3=CC(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N6)=C6C=C3)(=O)=O
• Molecular Weight: 757.28
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported